Cheap arthritis drug may keep bypass grafts working longer

NCT ID NCT07569328

Not yet recruiting Prevention Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a low dose of colchicine (0.5 mg) every day for two years after coronary artery bypass grafting (CABG) can prevent the new blood vessel grafts from failing. About 622 adults who just had bypass surgery will be randomly assigned to get either colchicine or a placebo pill, on top of standard heart medications. The main goal is to see if colchicine reduces the rate of graft blockage or narrowing, as measured by a CT scan at 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Colchicine (0.5 mg pill daily)
What this could lead to: If it works, this could provide a simple, low-cost way to keep bypass grafts open longer, reducing the need for repeat procedures.
What could go wrong: This is a single-center trial that hasn't started recruiting yet. Colchicine can cause digestive issues or muscle pain, and the benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colchicine poisoning coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABG CAD - CORONARY ARTERY DISEASE COLCHICINE

Contacts and locations

Locations

Beijing Anzhen Hospital

Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.